• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
CAI Yunjie,LIN Ang.Research progress of the safety and toxicity of mRNA-LNP drugs[J].Journal Of Pharmaceutical Research,2025,44(9):900-904,936[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 1952times   Download 736次 QR Code for this article
Scan with your phone!
mRNA-LNP药物安全性及毒性研究进展
蔡云洁1,2,林昂1,2
Font:Larger+|Default|Smaller-
(1.中国药科大学基础医学与临床药学学院,江苏 南京 211198;2.中国药科大学新药安全评价研究中心,江苏 南京 211198)
摘要:
mRNA技术已经成为生物医学领域的革命性技术,特别是在新冠大流行期间,mRNA疫苗极大降低了重症的发生率和死亡率。然而,随着该技术在临床治疗中的日益普及,安全性问题逐渐成为研究和应用的焦点,尤其是关于潜在毒性风险的管理与解决策略。随着mRNA技术在临床应用范围的不断扩大,迫切需要解决这些安全性挑战,以保障mRNA技术的长期可持续发展。本综述介绍了mRNA药物组分的致炎机制,展望了提升mRNA药物安全性的途径。
关键词:  mRNA药物  脂质纳米颗粒  可电离脂质  炎症反应
DOI:10.13506/j.cnki.jpr.2025.09.012
基金项目:国家自然科学基金项目(No.32471004)
Publication Date:September 25, 2025
Research progress of the safety and toxicity of mRNA-LNP drugs
CAI Yunjie1,2,LIN Ang1,2
(1. School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198,China;2. Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198,China)
Abstract:
mRNA technology has become a revolutionary technique in the biomedical field, especially during the COVID-19 pandemic when SARS-CoV-2 mRNA vaccines were widely used and largely helped to mitigate disease burden globally. However, with continuous expansion of the clinical applications of mRNA technology, its safety issues have caused major concerns and urged management of potential toxicity risks. In this concise review, we summarize current studies on the induction of undesired inflammation by mRNA drug formulations, and further discussed potential approaches that can be utilized to tackle this challenge.
Key words:  mRNA drug  Lipid nanoparticle  Ionizable lipid  Inflammatory responses
Today's Visits:487    Total Visits:2383201
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.